- Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients
-
Yuen MF, Chuang WL, Peng CY, Jeng WJ, Su WW, Chang TT, Chen CY, Hsu YC, De La Rosa G, Ahmad A, Luo E, Conery AL
- KMID: 2557390
- Clin Mol Hepatol.
- 2024 Jul;30(3):375-387.
- doi: 10.3350/cmh.2023.0535
Background/Aims: Oral EDP-514 is a potent core protein inhibitor of hepatitis B virus (HBV) replication, which produced a >4-log viral load reduction in HBV-infected chimeric mice with human liver cells.... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients
-
Hou J, Gane E, Balabanska R, Zhang W, Zhang J, Lim TH, Xie Q, Yeh CT, Yang SS, Liang X, Komolmit P, Leerapun A, Xue Z, Chen E, Zhang Y, Xie Q, Chang TT, Hu TH, Lim SG, Chuang WL, Leggett B, Bo Q, Zhou X, Triyatni M, Zhang W, Yuen MF
- KMID: 2554426
- Clin Mol Hepatol.
- 2024 Apr;30(2):191-205.
- doi: 10.3350/cmh.2023.0422
Background/Aims: Four-week treatment of linvencorvir (RO7049389) was generally safe and well tolerated, and showed anti-viral activity in chronic hepatitis B (CHB) patients. This study evaluated the efficacy, safety, and pharmacokinetics... -
- CITED
-
- Close
- SHARE
-
- Close
